Showing 1271-1280 of 10904 results for "".
- Analysis Identifies Distinct Keratinocyte and Fibroblast Niches in Severe HShttps://practicaldermatology.com/news/study-examines-pathogenic-keratinocyte-states-and-fibroblast-niches-in-severe-hs/2488815/Researchers identified a pathogenic keratinocyte state and spatially distinct fibroblast populations in severe hidradenitis suppurativa (HS), providing new insights into epithelial–stromal and immune cell interactions that may contribute to disease persistence. The study authors, publishin
- Study: Bimekizumab Achieves Complete Psoriasis Clearance in Most Patients at 2 Yearshttps://practicaldermatology.com/news/bimekizumab-achieves-complete-psoriasis-clearance-in-most-of-patients-at-2-years-study/2488814/A 2-year multicenter real-world study published in the Journal of the American Academy of Dermatology (JAAD) found that 71.1% of adults with plaque psoriasis treated with bimekizumab achieved complete skin clearance, with treatment persistence approaching 89% at week 104. The retrospective
- IL-23 Inhibitors Associated With Lowest Psoriatic Arthritis Incidence: Studyhttps://practicaldermatology.com/news/il-23-inhibitors-associated-with-lowest-psoriatic-arthritis-incidence-study/2488799/IL-23 Inhibitors Associated With Lowest Psoriatic Arthritis Incidence in Comparative Study Patients with psoriasis treated with interleukin (IL)-23 inhibitors had a lower observed incidence of psoriatic arthritis (PsA) than those receiving Janus kinase (JAK) inhibitors or IL-17 inhibitor
- Lutikizumab Meets Primary Endpoint in Phase 3 Hidradenitis Suppurativa Trialhttps://practicaldermatology.com/news/lutikizumab-meets-primary-endpoint-in-phase-3-hidradenitis-suppurativa-trial/2488774/AbbVie announced positive topline results from the Phase 3 INTREPID trial evaluating lutikizumab, an investigational dual IL-1α/IL-1β antagonist, in adults and adolescents with moderate-to-severe hidradenitis suppurativa (HS). The randomized, double-blind, placebo-co
- National Rosacea Society Awards $25,000 for Research on Rosacea Pathogenesis and Treatmenthttps://practicaldermatology.com/news/national-rosacea-society-awards-25000-for-research-on-rosacea-pathogenesis-and-treatment/2488784/The National Rosacea Society (NRS) has awarded two research grants totaling $25,000 to support investigations into the underlying mechanisms of rosacea, including vascular inflammation, immune system interactions, and the potential association between Helicobacter pylori infection and di
- Melanoma Risk Prediction Models Show Moderate Accuracy in Large Australian Cohorthttps://practicaldermatology.com/news/melanoma-risk-prediction-models-show-moderate-accuracy-in-large-australian-cohort/2488770/Six published melanoma risk prediction models demonstrated varying accuracy in identifying individuals who developed melanoma, with most underestimating absolute risk, according to a cohort study published in JAMA Dermatology. Melanoma Risk Prediction Accuracy and Study Findings<
- Sun Pharma, Mount Sinai Leaders Discuss Long-Term Vision Behind $2.5 Million Dermatology Endowmenthttps://practicaldermatology.com/news/sun-pharma-mount-sinai-leaders-discuss-long-term-vision-behind-25-million-dermatology-endowment/2488752/Sun Pharma’s’ $2.5 million endowed professorship at the Icahn School of Medicine at Mount Sinai represents an extension of a longstanding collaboration centered
- Study: Acupressure Improves Rosacea Severity, Reduces Inflammatory Biomarkershttps://practicaldermatology.com/news/study-acupressure-improves-rosacea-severity-reduces-inflammatory-biomarkers/2488756/Device-free auricular acupressure improved clinical outcomes and reduced inflammatory biomarkers in patients with rosacea receiving standard first-line treatment, according to findings from a trial published in JAMA Dermatology. The randomized, single-center, sham-controlled, asse
- Fall Clinical Talk Highlights KIT Inhibition's Promise for Chronic Spontaneous Urticariahttps://practicaldermatology.com/news/fall-clinical-talk-highlights-kit-inhibitions-promise-for-chronic-spontaneous-urticaria/2488733/Emerging evidence supports KIT inhibition as a novel therapeutic approach, Naiem Issa, MD, PhD, FAAD, said in a talk at the 2026 Fall Clinical Dermatology Conference. Targeting the KIT signaling pathway may offer a new treatment strategy for patients with chronic spontaneous urticaria (CSU
- Bimekizumab-Treated Patients With Hidradenitis Suppurativa Remained Flare-Free Through 3 Years in Extension Studyhttps://practicaldermatology.com/news/bimekizumab-treated-patients-with-hidradenitis-suppurativa-remained-flare-free-through-3-years-in-extension-study/2488712/Most evaluable patients with moderate-to-severe hidradenitis suppurativa (HS) receiving bimekizumab remained free of observed flares through 148 weeks, according to pooled BE HEARD I and II and BE HEARD EXT data presented at the 2026 Fall Clinical Dermatology Conference. The analysis inclu